Flash Finance

IOL Chemicals and Pharmaceuticals LimitedIOLCPCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹194.69
MCap ₹5,715 Cr · P/E 34.0
IOL Chemicals and Pharmaceuticals Limited — Stock analysis & AI research IOL Chemicals and Pharmaceuticals Limited — Multibagger AI analysis IOL Chemicals and Pharmaceuticals Limited — Seasonality — best & worst months IOL Chemicals and Pharmaceuticals Limited — Technical indicators & charts IOL Chemicals and Pharmaceuticals Limited — Technical setup — score, trend, support & resistance IOL Chemicals and Pharmaceuticals Limited — Live exchange announcements
📋 High Interest Coverage Stocks📋 Stocks With Strong Quarterly Results📋 Promoters Increasing Stake 📈 Bollinger Squeeze Stocks📈 Relative Strength Leaders📈 Volume Dry-Up Stocks📈 Multi-Timeframe Bullish Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹756 Cr
Sales · Jun 2026
+37.1% YoY
₹103 Cr
Operating Profit · Jun 2026
+66.5% YoY
13.7%
OPM % · Jun 2026
+21.2% YoY
₹64 Cr
Net Profit · Jun 2026
+89.8% YoY
₹2.19
EPS · Jun 2026
+88.8% YoY

📝 IOL Chemicals and Pharmaceuticals Limited — results explained

Quarter ended June 2026 (Q1 FY27)

IOL Chemicals and Pharmaceuticals Limited reported revenue of ₹756 crore for the quarter ended June 2026 (Q1 FY27), up 37.1% from ₹552 crore in the same quarter last year, and up 22.2% sequentially over the March 2026 quarter.

Net profit rose 89.8% year-on-year to ₹64 crore, from ₹34 crore. Earnings per share (EPS) came in at ₹2.19.

Operating profit stood at ₹103 crore — an operating margin (OPM) of 13.7%, compared with 11.3% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, IOL Chemicals and Pharmaceuticals Limited posted revenue of ₹2,319 crore, a growth of 11.5% over FY25, with a net profit of ₹137 crore (up 36.6% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹2,523 crore with a net profit of ₹168 crore.

Valuation snapshot

At the current price of ₹194.69, IOLCP has a market capitalisation of ₹5,715 crore and a trailing P/E of about 34.0.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 8th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 62.28%, foreign institutional investors (FIIs) 7.25%, domestic institutional investors (DIIs) 0.30%, public shareholders 30.17% of IOL Chemicals and Pharmaceuticals Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹5,715 Cr
Current Price ?
₹194.7
P/E ?
34.03below ind
Industry P/E ?
37.20
P/B ?
3.18
P/S ?
2.26
P/FCF ?
132.90
Enterprise Value ?
₹5,850 Cr
EV/EBITDA ?
18.88
PEG ?
17.01
Earnings Yield ?
3.9%
Dividend Yield ?
0.50%
Profitability & Returns
Sales (TTM) ?
₹2,523 Cr
OPM ?
12.3%
Profit after tax (TTM) ?
₹168 Cr
EPS (TTM) ?
₹5.72
ROCE ?
11.0%
ROE ?
9.3%
ROA ?
6.5%
Growth
Sales — latest qtr ?
₹756 Cr
PAT — latest qtr ?
₹64 Cr
YoY qtr sales growth ?
37.1%
YoY qtr profit growth ?
89.8%
Sales growth (3y) ?
2%
Sales growth (5y) ?
N/A
Profit growth (3y) ?
2%
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹135 Cr
Debt to Equity ?
0.08
Interest Coverage ?
13.1
Current Ratio ?
N/A
Ownership
Promoter holding ?
62.28%
Change in promoter holding ?
9.66%
Pledged percentage ?
N/A
Market
Return 3 months ?
31.3%
Return 6 months ?
113.6%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 523587563545520504502526523528552568580619756 +37.1% +22.2%
Operating Profit 4395736444505142476362575792103 +66.5% +12.5%
Other Income 797788764577528 +11.0% +309.0%
Interest 554443244443434 -13.9% +21.3%
Depreciation 121214161616171819192020202021 +7.9% +6.7%
Profit Before Tax 338761513237402628454640287187 +90.5% +22.1%
Net Profit 246546382328301921313430215364 +89.8% +21.5%
EPS 4.0511.037.816.453.934.715.113.263.501.071.161.020.701.812.19 +88.8% +21.0%
OPM % 8.2% 16.2% 12.9% 11.8% 8.5% 9.8% 10.2% 7.9% 9.0% 11.9% 11.3% 10.1% 9.9% 14.9% 13.7% +21.2% -8.1%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹2,079 Cr ₹2,319 Cr ₹2,523 Cr +11.5%
Operating Profit ₹203 Cr ₹268 Cr ₹310 Cr +32.6%
OPM % 9.74% 11.58% 12.28% +18.9%
NPM % 4.84% 5.93% 6.66% +22.5%
Other Income ₹23 Cr ₹22 Cr ₹22 Cr -5.9%
Depreciation ₹72 Cr ₹80 Cr ₹82 Cr +10.4%
Interest ₹15 Cr ₹14 Cr ₹14 Cr -2.6%
EBIT ₹130 Cr ₹189 Cr ₹228 Cr +44.9%
PBT ₹138 Cr ₹185 Cr ₹226 Cr +33.5%
Tax ₹24 Cr ₹29 Cr ₹40 Cr +23.1%
Net Profit ₹101 Cr ₹137 Cr ₹168 Cr +36.6%
EPS ₹12.94 ₹4.69 ₹5.72 -63.8%
Material Cost ₹1,011 Cr ₹1,100 Cr ₹1,231 Cr +8.8%
Employee Cost ₹164 Cr ₹178 Cr ₹191 Cr +8.4%
Extraordinary Items — ₹11 Cr ₹11 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 59595959 +0.0%
Reserves 1,4491,5531,6291,740 +6.8%
Borrowings 8033117135 +15.4%
Other Liabilities 435600577653 +13.2%
Total Liabilities 2,0222,2442,3822,587 +8.6%
Fixed Assets 7529331,1711,184 +1.1%
CWIP 901012294 +327.3%
Investments 20202121 +0.0%
Other Assets 1,1611,1901,1691,289 +10.3%
Total Assets 2,0222,2442,3822,587 +8.6%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 122290179214 +19.6%
Cash from Investing Activity -120-191-154-198 -28.6%
Cash from Financing Activity -4-9246-29 -163.0%
Net Cash Flow -2670-13 -118.6%
Free Cash Flow -8717-3443 +226.5%
CFO/OP 75%144%97%94% -3.1%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 83819095 +5.6%
Inventory Days 771119591 -4.2%
Days Payable 74123112118 +5.4%
Cash Conversion Cycle 86697368 -6.8%
Working Capital Days 72715853 -8.6%
ROCE % 14%12%9%11% +22.2%

👥 Shareholding (latest 6 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026 % Chg
Promoters 52.62%52.62%52.62%57.48%62.28%62.28% +0.0%
FIIs 2.59%2.25%2.08%1.72%4.87%7.25% +48.9%
DIIs 0.02%0.05%0.03%0.02%0.43%0.30% -30.2%
Public 44.76%45.10%45.26%40.78%32.42%30.17% -6.9%
No. of Shareholders 1,25,0401,36,1291,33,5311,31,5501,19,3111,32,241 +10.8%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 KOPRAN Kopran ₹281.55 1,361 54.5 700 25 8.7% 3.6% -96.0% -97.6% 13.9% -10.0%
❓ Frequently asked questions
What was IOL Chemicals and Pharmaceuticals Limited's revenue in Q1 FY27?
IOL Chemicals and Pharmaceuticals Limited reported revenue of ₹756 crore for the quarter ended June 2026 (Q1 FY27), up 37.1% from ₹552 crore in the same quarter last year, and up 22.2% sequentially over the March 2026 quarter.
What was IOL Chemicals and Pharmaceuticals Limited's net profit in Q1 FY27?
Net profit rose 89.8% year-on-year to ₹64 crore, from ₹34 crore. Earnings per share (EPS) came in at ₹2.19.
What is IOLCP's market capitalisation and P/E ratio?
At the current price of ₹194.69, IOLCP has a market capitalisation of ₹5,715 crore and a trailing P/E of about 34.0.
Who owns IOL Chemicals and Pharmaceuticals Limited? (shareholding pattern)
As of Sep 2026, promoters held 62.28%, foreign institutional investors (FIIs) 7.25%, domestic institutional investors (DIIs) 0.30%, public shareholders 30.17% of IOL Chemicals and Pharmaceuticals Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI